S
Sharianne G. Louie
Researcher at Pfizer
Publications - 8
Citations - 4204
Sharianne G. Louie is an academic researcher from Pfizer. The author has contributed to research in topics: Receptor tyrosine kinase & Myeloid leukemia. The author has an hindex of 8, co-authored 8 publications receiving 4107 citations. Previous affiliations of Sharianne G. Louie include Oregon Health & Science University.
Papers
More filters
Journal Article
In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors Determination of a Pharmacokinetic/Pharmacodynamic Relationship
Dirk B. Mendel,A. Douglas Laird,Xiaohua Xin,Sharianne G. Louie,James G. Christensen,Guangmin Li,Randall E. Schreck,Tinya Abrams,Theresa J. Ngai,Leslie Lee,Lesley J. Murray,Jeremy P. Carver,Emily Chan,Katherine G. Moss,Joshua Ö. Haznedar,Juthamas Sukbuntherng,Robert A. Blake,Li Sun,Cho Tang,Todd W. Miller,Sheri Shirazian,Gerald Mcmahon,Julie M. Cherrington +22 more
TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.
Journal ArticleDOI
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.
Anne Marie O'Farrell,Tinya Abrams,Helene A. Yuen,Theresa J. Ngai,Sharianne G. Louie,Kevin W.H. Yee,Lily Wong,Weiru Hong,Leslie Lee,Ajia Town,Beverly D. Smolich,William C. Manning,Lesley J. Murray,Michael Heinrich,Julie M. Cherrington +14 more
TL;DR: The in vivo efficacy of SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the subcutaneous tumor xenograft model and prolongs survival in the bone marrow engraftment model, suggesting that further exploration of SU 11248 activity in AML patients is warranted.
Journal ArticleDOI
A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.
Walter Fiedler,Hubert Serve,Hartmut Döhner,Michael Schwittay,Oliver G. Ottmann,Anne-Marie O'Farrell,Carlo L. Bello,Randy Allred,William C. Manning,Julie M. Cherrington,Sharianne G. Louie,Weiru Hong,Nicoletta Brega,Giorgio Massimini,Paul Scigalla,Wolfgang E. Berdel,Dieter K. Hossfeld +16 more
TL;DR: Monotherapy with SU11248 induced partial remissions of short duration in acute myeloid leukemia (AML) patients, and further evaluation of this compound, for example in combination with chemotherapy, is warranted.
Journal Article
An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients
Anne Marie O'Farrell,James M. Foran,Walter Fiedler,Hubert Serve,Ron Paquette,Maureen Cooper,Helene A. Yuen,Sharianne G. Louie,Heidi Kim,Susan L Nicholas,Michael Heinrich,Wolfgang E. Berdel,Carlo L. Bello,Mark Jacobs,Paul Scigalla,William C. Manning,Stephen Kelsey,Julie M. Cherrington +17 more
TL;DR: This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients and accomplishes a crucial milestone in the development of novel oncology therapeutics.
Journal ArticleDOI
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
Francis J. Giles,Alison Stopeck,Lewis R. Silverman,Jeffrey E. Lancet,Maureen Cooper,Alison L. Hannah,Julie M. Cherrington,Anne Marie O'Farrell,Helene A. Yuen,Sharianne G. Louie,Weiru Hong,Jorge E. Cortes,Srdan Verstovsek,Maher Albitar,Susan O'Brien,Hagop M. Kantarjian,Judith E. Karp +16 more
TL;DR: Single agent SU5416 had biologic and modest clinical activity in refractory AML/MDS and studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML or MDS.